Novel regulation of keratin gene expression by thyroid hormone and retinoid receptors by TomicCanic, M et al.
Novel Regulation of Keratin Gene Expression by Thyroid Hormone
and Retinoid Receptors*
(Received for publication, October 30, 1995)
Marjana Tomic´-Canic´‡§¶, Doris Day‡, Herbert H. Samuelsi**, Irwin M. Freedberg‡ ‡‡, and
Miroslav Blumenberg‡§§¶¶
From the ‡Ronald O. Perelman Department of Dermatology, iDepartment of Medicine, **Department of Pharmacology,
‡‡Department of Cell Biology, and §§Department of Biochemistry, New York University Medical Center, New York, New
York 10016 and the §Institute Vinca, 11000 Belgrade, Yugoslavia
Expression of keratin proteins, markers of epider-
mal differentiation and pathology, is uniquely regu-
lated by the nuclear receptors for retinoic acid (RAR)
and thyroid hormone (T3R) and their ligands: it is
constitutively activated by unliganded T3R, but it is
suppressed by ligand-occupied T3R or RAR. This reg-
ulation was studied using gel mobility shift assays
with purified receptors and transient transfection as-
says with vectors expressing various receptor mu-
tants. Regulation of keratin gene expression by RAR
and T3R occurs through direct binding of these recep-
tors to receptor response elements of the keratin gene
promoters. The DNA binding “C” domain of these re-
ceptors is essential for both ligand-dependent and -in-
dependent regulation. However, the NH2-terminal
“A/B” domain of T3R is not required for either mode of
regulation of keratin gene expression. Furthermore,
v-ErbA, an oncogenic derivative of cT3R, also activates
keratin gene expression. In contrast to the previously
described mechanism of gene regulation by T3R, het-
erodimerization with the retinoid X receptor is not
essential for activation of keratin gene expression by
unliganded T3R. These findings indicate that the
mechanism of regulation of keratin genes by RAR and
T3R differs significantly from the mechanisms de-
scribed for other genes modulated by these receptors.
Hormones and vitamins, such as thyroid hormone (T3)1 and
all-trans-retinoic acid (RA), are important regulators of devel-
opment and differentiation in general and of the epidermis in
particular. The effects of vitamin A, a precursor of RA, on the
skin were observed first in 1922 (1). Since that time, the skin
has been a model tissue for the study of RA action. It has been
shown that hypovitaminosis A causes epidermal hyperkerati-
nization, while non-keratinizing tissues, such as conjunctiva
and cornea, become keratinized. Conversely, hypervitaminosis
A causes inhibition of keratinization, hyperplasia, and a block
of terminal differentiation (1–6). Similarly, thyroid hormone
deficiency results in a number of skin changes, including hy-
perkeratosis (7–10), and the thyroid hormone excess causes
increased epidermal cell division (11). Similar effects of RA and
T3 were observed in keratinocytes in vitro (2, 9, 12).
Keratins are the intermediate filament network proteins in
many epithelia. Their expression is precisely controlled in var-
ious physiological and pathological states of the epidermis.
When the basal keratinocyte becomes detached from the base-
ment membrane, its commitment to differentiation is an-
nounced by suppression of the basal cell-specific keratins K5/
K14 and the induction of the differentiation-specific keratins
K1/K10 (13, 14). In wound healing and other hyperproliferative
processes, keratinocytes express the activation-specific keratin
pair K6/K16 (15, 16). During inflammation, keratin K17 is
expressed, whereas transformed keratinocytes express kera-
tins K8/K18 (17, 18).
Because a fairly large number of keratin genes are sup-
pressed by RA and T3, these genes provide a unique opportu-
nity to study the mechanisms of negative regulation by T3R
and RAR on native regulatory elements. We have reported
previously that keratin gene expression is suppressed by RA or
T3 (19–21). To examine this regulation in more detail, we
studied the response of three different keratin promoter-CAT
constructs (K5, K14, K17) to RAR or T3R, in the presence or
absence of their cognate ligands using mutants of T3R in trans-
fection and gel mobility shift experiments (22–24). These pro-
moters were chosen because K5 and K14 keratins are specific
for the basal layer of the epidermis, the layer most proximal to
the source of RA in vivo, whereas K17, although not present in
healthy skin, is a marker of various inflammatory processes.
Furthermore, all three promoters are expressed at high levels
when transfected into cells of epithelial origin.
Our results show that T3R regulates keratin genes in a
unique manner: unliganded T3R leads to activation while the
addition of T3 results in suppression. The NH2-terminal “A/B”
domain of cT3Ra is not required for keratin gene regulation
while the ligand binding and the DNA binding domains are
essential. In addition, we found that v-ErbA is a constitutive
activator of keratin genes and that it blocks ligand-dependent
suppression by T3R and RAR. Furthermore, we found that T3R
does not form heterodimers with RXR when bound to K14RE,
and that addition of T3 promotes monomer binding at the
expense of the homodimer. Last, mutants which do not form
heterodimers with RXR do mediate constitutive activation of
keratin genes. Taken together these results suggest that the
regulation of keratin genes may be mediated by monomers, or
perhaps homodimers, of T3R.
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MATERIALS AND METHODS
Plasmids and Their Growth and Purification—Plasmids pK#14CAT,
pK#5CAT pK#17CAT, and pRSVZ have been described previously (13,
17). The plasmids containing human RARa, RARb, and RARg nuclear
receptors were gifts from Dr. P. Chambon. Plasmids cT3Ra(51–408),
NH2-terminal deletion mutant of T3R, cT3Ra(120–408) DBD
2 mutant,
heptad mutants cT3Ra(L365R) and cT3Ra(L372R), and v-ErbA were
also described previously (23, 24, 26).2 Plasmids were grown in JM101
Escherichia coli host to saturation density in LB medium. DNA was
extracted and purified using the Magic Mega Prep Kit from Promega.
Cell Growth—HeLa cells were maintained in Dulbecco’s modified
Eagle’s medium supplemented with 10% calf serum at 37 °C in a 5%
CO2 atmosphere in media containing penicillin and streptomycin as
described (20, 27). The day before transfection, cells were plated onto
60-mm dishes. Four hours before transfection the medium was changed
to DMEM supplemented with 10% calf serum depleted of RA and T3 as
described (20).
Transfection Using Ca3(PO4)2—We have generally followed pub-
lished procedure for cells that were at 80% confluence (27). At the time
of transfection into each dish were added 3 mg of the CAT plasmid, 1 mg
of the nuclear receptor expression vector plasmid, 1 mg of pRSVZ ref-
erence plasmid and a sufficient amount of carrier to bring the total to 10
mg of DNA. The cells were harvested 48 h after transfection by scraping
into 5 ml of phosphate-buffered saline, washed once more in phosphate-
buffered saline, and resuspended in 150 ml of 0.25 M Tris buffer, pH 7.8.
All transfections were performed in duplicate plates, and each trans-
fection experiment was repeated two to five times. CAT and b-galacto-
sidase assay were performed as described (20).
Electrophoretic Gel Mobility Shift Assays—E. coli-expressed hRARa
and cT3Ra were purified as described previously (28). Oligonucleotides
were synthesized on a Pharmacia Gene Assembler Plus Synthesizer.
The sequence of oligonucleotides flanked by HindIII overhangs (59-
AGCTT-39) are as follows: TREp, AGGTCATGACCT; mTRE, ACGT-
CATGACGT; K14RE, GCTAGCCTGTGGGTGATGAAAGCCAAG-
GGGAATGT. Double-stranded oligonucleotides corresponding to the
K14RE and TRE palindrome were labeled with [a-32P]dATP, using the
Klenow fragment of E. coli DNA polymerase I. 30,000 cpm of the
resulting probe was mixed with 2.5 fmol of purified receptor proteins
and incubated first for 30 min at room temperature then for 10 min at
14 °C. The incubation was done in a 30-ml volume in 25 mM Tris, pH
7.8, 500 mM EDTA, 88 mM KCl, 10 mM 2-b-mercaptoethanol, 0.1 mg of
aprotinin, 0.1 mg of poly(dI-dC), 0.05% Triton X-100 (v/v), 10% glycerol
(v/v). Samples were loaded on 4% polyacrylamide gel and separated by
electrophoresis (20–25 mA) at 14 °C for 2 h with a buffer containing 10
mM Tris, 7.5 mM acetic acid, and 40 mM EDTA, pH 7.8. Gels were dried
and analyzed by autoradiography.
Competition experiments were performed as follows: a 100 M excess
of the competitor DNA was incubated with protein at room temperature
for 15 min prior to addition of the radioactively labeled DNA probe.
Binding reactions were further incubated at room temperature for 15
min and then at 14 °C for additional 10 min.
cT3Ra(L372R) was obtained by in vitro translation using TNT T7-
coupled Reticulocyte Lysate System from Promega with 1.5 mg of puri-
fied DNA. The wild type cT3Ra receptor was used as a control. The
quality of both synthesized proteins was analyzed by SDS-gel electro-
phoresis and autoradiography. The relative amount at cT3Ra(L372R)
protein was compared with wild type cT3Ra and determined by quan-
titating the incorporated 35S corrected for the number of methionine
residues per protein. One ml of reticulocyte lysate translated receptor
was used in the binding reaction, in the presence of RNase A (0.5 mg)
and RNase T1 (1.5 units) as described (23).
RESULTS
Novel Regulation of the Keratin Promoters by Retinoic Acid
and Thyroid Hormone Receptors—To analyze regulation of ker-
atin gene expression by RA and T3 we used the promoters of
the K14, K5, and K17 keratin genes linked to a CAT reporter
gene. HeLa cells were co-transfected with the keratin promot-
er-CAT constructs along with vectors expressing wild type and
mutants of chicken T3Ra and human RARs in the presence or
absence of the respective ligands. We chose HeLa cells because
we have shown previously that transfected keratin gene pro-
moters behave identically in HeLa cells and in human epider-
mal keratinocytes (20, 21). However, the endogenous receptors
are expressed at much lower levels in HeLa cells, which facil-
itates the interpretation of results with transfected receptors.
In the absence of RA, the RARs are without effect (Fig. 1). In
the presence of RA, all three retinoic acid receptors (hRARa,
hRARb, and hRARg) suppress expression of each of the keratin
gene promoters 5- to 6-fold (Fig. 1). In contrast, TREpCAT,
containing an optimized thyroid hormone/retinoic acid re-
sponse element, was stimulated approximately 30-fold by all
three receptors in the presence of RA.
To test whether T3 also regulates keratin gene expression,
we co-transfected HeLa cells with the keratin-promoter CAT
constructs and a cT3Ra expression vector and then incubated
the cells in the presence or absence of T3. As previously found,
the control reporter TREpCAT is stimulated approximately
35-fold by T3 and suppressed by unliganded T3R approxi-
mately 8-fold (23, 29). In contrast, cT3Ra has the opposite
effect on keratin gene expression: unliganded T3R stimulates
keratin K5, K14, and K17 gene promoters approximately
3-fold, whereas with T3 the basal expression of the three ker-
atin promoter constructs is inhibited about 5-fold (Fig. 1). Com-
paring the results in Fig. 1 we find that RAR and T3R mediate
ligand-dependent inhibition of keratin gene activity with sim-
ilar efficiency.
To analyze the combined effect of T3R and RAR on the
regulation of keratin gene promoters, both receptors were ex-
pressed using 5-fold more cT3Ra expression vector. Unliganded
T3R blocked both the ligand-dependent inhibition of keratin
genes by hRARa and the ligand-dependent stimulation of
TREpCAT (Fig. 2). Conversely, when hRARa was expressed in
a 5-fold excess over cT3Ra, it did not block the constitutive
activation of keratin gene expression by unliganded T3R. In the
presence of its ligand, however, hRARa was epistatic and com-
pletely blocked the activation by cT3Ra (Fig. 2). The effects of
RA without co-transfected hRARa are due to the low levels of
endogenous RARa.
hRARa and cT3Ra Bind to a Functional Element in the K14
Gene Promoter—To study the interaction of T3R and RAR with
receptor-responsive sequences, we focused on the 296/251 re-
gion of the K14 gene promoter in which we previously identi-
fied a TRE/RARE using site-specific mutagenesis (21). Gel mo-
bility shift DNA binding assays were performed using hRARa
and cT3Ra expressed and purified from E. coli (Fig. 3).
cT3Ra formed two mobility complexes with the K14RE
probe, the monomer and the homodimer (28). cT3Ra predomi-
nantly binds K14RE as a homodimer. Binding is specific be-
cause it can be efficiently competed with a 100 M excess of cold
K14RE and consensus TREpal. A mutated TREpal that does
not bind cT3Ra (28) does not compete for the binding of cT3Ra
to K14RE (Fig. 3).
Similarly, hRARa predominantly forms a homodimer com-
plex with K14RE (Fig. 3). Binding is specific because it can be
competed with an excess of K14RE or TREpal but not with
mTRE. These results confirm that the 295/251 region of the
K14 promoter contains a functional TRE/RARE that binds both
cT3Ra and hRARa receptors.
Because the addition of T3 changes transcriptional regula-
tion from stimulation to repression, we investigated the effects
of ligand binding. Interestingly, the addition of T3 dramatically
inhibits the formation of homodimers of cT3Ra while increas-
ing the monomer binding to K14RE (Fig. 4A). In contrast,
addition of RA did not change the binding pattern of hRARa. A
small change in mobility is due to the conformational change
caused by ligand binding to the receptor (28).
The presence of T3 or RA did not change the pattern of
2 Helmer, E., Raaka, B. M., and Samuels, H. H. (1996) Endocrinology
137, in press.
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binding of cT3Ra or hRARa to the TREpal as shown in Fig. 4B.
Again there is small change in mobility of the complexes due to
a conformational change. The K14RE has a lower binding af-
finity when compared with the optimized TREpal sequence,
which is similar to other previously described native TRE/
RAREs (30, 31).
We analyzed the combined effects of the receptors using gel
mobility shift assays. In the absence of ligands three different
complexes were detected: homodimers of cT3Ra, heterodimers
of cT3Ra/RARa, and homodimers of hRARa (Fig. 4A, last four
lanes). Addition of T3 inhibited the binding, whereas addition
of RA did not affect it.
The Amino-terminal Region of the T3R Is Not Essential for
Keratin Gene Regulation—To study the mechanism of keratin
regulation by cT3Ra, we used variants of the receptor that have
specific deletions and mutations in the NH2-terminal A/B re-
gion, the DNA binding domain, or the ligand and heterodimer-
ization domains, as well as v-ErbA (22–24). We first analyzed
the role of the 50-amino acid NH2-terminal region of cT3Ra,
because this region has been reported to be important for
hormone-independent activation of a sequence in the Rous
sarcoma virus LTR (RSV-LTR) (22, 32). The receptor mutant
cT3Ra(51–408) has a complete deletion of the 50-amino acid
NH2-terminal A/B domain but has normal DNA binding and
ligand binding properties (22). Both in the absence and in the
presence of T3, cT3Ra(51–408) functions essentially identical
to the wild type cT3Ra (compare Fig. 5A with Fig. 1). Thus, the
NH2-terminal A/B region of cT3Ra is not essential for either
constitutive activation or ligand-dependent inhibition of kera-
tin promoter activity.
The DNA Binding Domain (DBD) of cT3Ra Is Essential for
Keratin Gene Regulation—In contrast with the cT3Ra(51–408),
a mutant lacking both the DNA binding domain and the NH2-
terminal A/B region (cT3Ra(120–408); also referred to as
FIG. 1. Regulation of keratin gene expression by RAR and T3R. Regulation of K5, K14, and K17 keratin promoters by T3R and RARa,
RARb, and RARg. The basic, unregulated activity of each CAT construct is designated as 1 to show -fold regulation by RAR and T3R. Numbers
on the left ordinate represent regulation of keratin genes, and the numbers on the right represent -fold regulation of the TREpCAT.
FIG. 2. Unliganded T3R blocks suppression of keratin gene
expression by RA and RARa. Note, however, that the unliganded
RARa does not block the induction by T3R.
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DBD2) (24), did not influence keratin promoter activity (Fig.
5B). cT3Ra(120–408) has been shown to act as a dominant
negative inhibitor of wild type T3Rs and RARs (26, 28), indeed
it blocked the RA-dependent stimulation of TREpCAT
(Fig. 6A). The inhibitory effect was enhanced by the addition of
T3 to the medium. Unexpectedly, the suppression of keratin
genes by hRARa was not affected by addition of the
cT3Ra(120–408) in the presence or absence of T3 (Fig. 5A).
In view of the fact that cT3Ra(120–408) has no effect on
regulation by hRARa, we were surprised to find that it blocks
the effects of cT3Ra (Fig. 6B). The cT3Ra(120–408) mutant
efficiently blocked both effects of wild type cT3Ra on the ker-
atin K14 gene promoter: constitutive activation by unliganded
receptor and the inhibition found in the presence T3. The
blocking effect is not mediated through direct competition for
the DNA binding, because cT3Ra(120–408) is not a DNA-
binding protein. The inhibition most likely result from the
dimeric interactions with cT3Ra (23, 24).
v-ErbA Constitutively Activates Keratin Gene Promoters—v-
ErbA is an oncogenic variant of cT3Ra that binds T3 with very
low affinity and constitutively represses promoters that con-
tain a number of positive regulatory elements, including the
TREp in TREpCAT (Fig. 7A) (24, 33, 34). In contrast with the
repression seen with other elements, we find that v-ErbA con-
stitutively activates the K5, K14, and K17 promoters about
2–3-fold, which is similar to the activation found for unliganded
wild type cT3Ra (Fig. 7A). v-ErbA has also been found to act as
a weak dominant negative inhibitor of wild type T3Rs and
RARs (24). This effect is thought to result from direct compe-
tition for the DNA binding site rather than from interference
FIG. 3. cT3Ra and hRARa specifically bind K14RE. Autoradio-
grams of the gel mobility shift assay with K14RE probe are presented
with cT3Ra (shown on the left) and hRARa (shown on the right).
Binding of both receptors is efficiently competed with 100 M excesses of
cold K14RE (Slf) and TREpal but not with mTRE DNA. Note significant
increase in the amount of free probe in lanes competed with K14RE and
TREpal.
FIG. 4. Effects of ligands on binding and dimerization of
cT3Ra and hRARa. Autoradiograms of the gel mobility shift assays
are presented with K14RE (A) and TREpal probe (B).
FIG. 5. The DNA binding domain is essential for the regulation
by T3R. A, the NH2-terminal mutant cT3Ra(51–408), which contains
the DBD, regulates expression of keratin gene promoters the same as
the wild type T3R (compare with Fig. 1). B, the cT3Ra(120–408) mu-
tant of the T3R, which lacks the DBD, does not regulate expression of
keratin gene promoters.
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with heterodimerization with RXR (24). In contrast to
cT3Ra(120–408), which did not affect inhibition by hRARa-
RA, we found that v-ErbA efficiently blocked the effect of
hRARa-RA (Fig. 7B). v-ErbA was equally efficient in blocking
T3-dependent suppression of keratin promoter activity by
cT3Ra (Fig. 7C). Thus, v-ErbA is not only a constitutive acti-
vator of keratin gene expression, but also an inhibitor of the
suppression of keratin genes mediated by RA and T3.
Constitutive Activation of Keratin Gene Expression by T3R
Does Not Require Heterodimerization with RXR—To study the
role of homo- and heterodimerization in the constitutive acti-
vation of keratin genes by cT3Ra, we used mRXRb and cT3Ra
receptors in our gel mobility shift experiments (Fig. 8A). cT3Ra
can bind as three complexes with TREpal in the presence of
mRXRb. These can be identified by size as T3R monomer, T3R
homodimer, and RXR-T3R heterodimer. Addition of T3 did not
change the binding pattern. In contrast RXR-T3R heterodimers
are not formed with K14RE (Fig. 8A). The two complexes iden-
tified are the monomer and the homodimer of T3R. The addi-
tion of hormone promotes monomer binding at the expense of
the homodimer. These results suggest that the regulation of
keratin gene expression does not require heterodimer forma-
tion with RXR. To investigate this possibility further, we used
two cT3Ra mutants in the ninth heptad of the ligand binding
domain, cT3Ra(L365R) and cT3Ra(L372R), which have been
FIG. 6. The DBD mutant specifically interferes with the regu-
lation by T3R and not by RAR. A, the cT3Ra(120–408) (DBD2)
mutant of the T3R does not block the suppression of keratin gene
expression by RARa. Note that it blocks the induction of the TREpCAT.
B, the cT3Ra(120–408) (DBD2) mutant efficiently blocks regulation of
K14 keratin gene expression by T3R, both the suppression and the
induction in the presence and absence of T3, respectively.
FIG. 7. Regulation by v-ErbA. A, by itself, v-ErbA constitutively
stimulates keratin gene expression. B, v-ErbA blocks suppression of the
keratin gene expression by RARa. C, v-ErbA blocks T3-dependent sup-
pression of the K14 gene expression and induction of TREpCAT by T3R.
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shown to be critical for heterodimerization with RXR (23).
These mutants bind to response elements as homodimers as
efficiently as the wild type cT3Ra, but do not bind as het-
erodimers with RXR in the absence of T3 (23). With
cT3Ra(L365R), but not with cT3Ra(L372R), T3 mediates a
conformational change that results in the formation of cT3Ra/
RXR heterodimers (23). The binding pattern at cT3Ra(L372R)
mutant was identical to that of the wild type receptor; it formed
two complexes with K14RE: the monomer and the homodimer
(Fig. 8B). The addition of mRXRb did not change the binding
pattern, as expected, because this mutant is not capable of
forming heterodimers with RXR receptors.
cT3Ra(L365R) stimulates the expression of TREpCAT in
the presence of T3, but does not suppress basal expression in
the absence of T3 (Fig. 8C). In contrast, cT3Ra(L365R) reg-
ulates keratin promoters similarly to wild type cT3Ra: it
activates without T3, while it suppresses keratin expression
in the presence of T3 (Fig. 8C). The mutant cT3Ra(L372R),
which does not form heterodimers with or without T3, does
not stimulate or repress TREpCAT, but can constitutively
activate keratin gene promoters (Fig. 8C). cT3Ra(L372R)
does not mediate negative regulation by T3 because it has a
very low affinity for ligand (23). Constitutive activation of
keratin promoters by the two mutants with the altered ninth
heptad, cT3Ra(L365R) and cT3Ra(L372R), together with the
results from gel mobility shift experiments support the no-
tion that T3-independent stimulation of keratin gene expres-
sion by T3R occurs by a mechanism that is independent of
heterodimerization with RXR.
DISCUSSION
The regulation of keratin gene expression by T3R and RAR
described in this study is the inverse of the more commonly
studied positive regulation of transcription. First, T3R without
T3 constitutively activates keratin gene expression instead of
silencing or suppressing the level of basal expression. Second,
in the presence of T3, the constitutive activation of T3R is not
only reversed, but the extent of transcriptional activity is fur-
ther inhibited approximately 5-fold below the level of basal
expression. Although RAR does not mediate constitutive acti-
vation, incubation with RA also leads to negative regulation. A
number of natural promoters have been reported to be nega-
tively regulated by either RAR or T3R and their ligands, but
not by both receptors (35, 36). However, the large family of
keratin genes is negatively regulated by both T3 and RA via
their cognate receptors. Furthermore, keratin genes are the
first group of genes reported which are not only suppressed by
T3R in the presence of its ligand, but are also activated by
unliganded T3R.
We provide three new lines of evidence for a direct effect of
RAR and T3R on keratin gene promoters. Previously we have
identified an RARE/T3RE in the K14 promoter using site-
specific mutagenesis (21). In this paper we have shown that the
identified responsive element physically binds nuclear recep-
tors. We also show that the oncogenic derivative v-ErbA is an
efficient competitor of the ligand-dependent regulation of ker-
atin gene expression by RAR and T3R. Since it appears that
v-ErbA acts by competing for DNA binding rather than by
formation of nonfunctional heterodimers (24), our data with
v-ErbA receptor support a direct regulatory mechanism. Fur-
thermore, deletion of the DBD from the T3R aborts keratin
gene regulation. Taken together, our results suggest that reg-
pare with Fig. 1), while cT3Ra(L372R) constitutively stimulates keratin
gene expression, similar to v-ErbA (Fig. 7A). Note the difference in
regulation of TREpCAT.
FIG. 8. Regulation of keratin gene expression by cT3Ra does
not involve heterodimerization with RXR. A, gel mobility shift
assays using TREpal (left panel) and K14RE (right panel) as probes
with purified cT3Ra and mRXRb receptors. B, autoradiogram of gel
mobility shift assays using K14RE probe with mutant cT3Ra(L372R)
receptor expressed in reticulocyte lysate system and purified mRXRb.
C, regulation by the two ninth heptad mutants of T3R. Mutant
cT3Ra(L365R) regulates keratin genes as does the wild type T3R (com-
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ulation occurs via a direct interaction between RAR or T3R and
keratin gene promoters.
Several different mechanisms of negative regulation by RAR
and T3R have been described in literature. One mechanism
involves blocking a positive transcription factor, such as AP1
(35–40). This mechanism is difficult to reconcile with the stim-
ulation of keratin gene expression by the unliganded T3R.
Furthermore, the negative regulation does not occur through
blocking an AP1 binding site, because the K14 promoter does
not appear to have an AP1 site and the apparent AP1 site in the
K5 promoter is not required for inhibition by RAR and T3R (41,
42). A second mechanism of negative regulation by T3R was
observed on the RSV-LTR in which T3 inhibits stimulation
mediated by unliganded T3R (32). Negative regulation of the
keratin genes differs from negative regulation of the RSV-LTR
because ligand not only blocks induction by the unliganded
receptor, but also suppresses basal expression by 5-fold. Fur-
thermore, regulation of the RSV-LTR (32), but not of the ker-
atin genes requires the A/B domains. Therefore, we conclude
that regulation of keratin gene expression by RAR and T3R
occurs through a distinct molecular mechanism.
To examine the molecular mechanisms through which regu-
lation of keratin gene regulation occurs, we used several mu-
tated T3Rs and tested their effects on regulation of keratin
gene expression. These mutant T3Rs include complete dele-
tions of the A and B domains, the DBD domain described above,
as well as v-ErbA, a native variant of T3R, and point mutations
in the ligand and heterodimerization domains. The results with
these mutants are summarized in Fig. 9.
We were particularly interested in the constitutive activa-
tion mediated by unliganded T3R. In this paper, we have iden-
tified several characteristics that make this regulation novel
and distinct. First, the constitutive activation elicited by unli-
ganded T3R does not appear to be mediated through the bind-
ing of T3R/RXR heterodimers. Evidence from studies with
ninth heptad mutants suggests that the activation of keratin
genes is mediated by T3R homodimers. However, our gel mo-
bility shift results suggest that the ligand-dependent inhibition
may be mediated by T3R monomers.
Second, constitutive activation by cT3Ra appears to involve
only a subset of the transactivation domains thought to be
important for ligand-dependent transcriptional activation by
T3R. Unlike the reduction in ligand-dependent transactivation
by T3R on several other native response elements (22), activa-
tion of keratin genes by unliganded cT3Ra does not require the
NH2-terminal A/B domain of the receptor. This also further
distinguishes activation of keratin gene expression from the
regulation of RSV-LTR by unliganded cT3Ra, which requires
the NH2-terminal region for constitutive activation (32). In
addition, v-ErbA also acts as a constitutive activator of keratin
gene expression. This indicates that the putative transactiva-
tion domain that is deleted in v-ErbA at the COOH-terminal
end of cT3Ra does not mediate constitutive activation (25).
Thus constitutive activation may be mediated by another, so
far unidentified, region of the receptor. This finding is consist-
ent with the previous observation that cT3Ra(1–392), which
lacks this putative activation domain, can constitutively acti-
vate the growth hormone or prolactin gene promoters in
GH4C1 cells (26).
This novel mechanism of gene regulation may be particularly
important in those tissues in which both T3 and RA play
important roles determine the cell phenotype. While in some
cells regulation that involves RXR integrates the response to
hormones and vitamins, in the epidermis the response to each
signal may need to be clearly distinct from responses to all
other signals. If so, the RXR-independent regulation described
here may provide the appropriate discrimination of signals
reaching the epidermis. We expect, however, that this novel
regulation operates in other systems as well.
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